RFS Failed as Endpoint in Adjuvant Immunotherapy Trials
A new analysis found that relapse-free survival is a poor surrogate endpoint for overall survival in adjuvant immunotherapy trials in a variety of cancer types.
Medscape Medical News
source https://www.medscape.com/viewarticle/994971?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/994971?src=rss
Comments
Post a Comment